Trials / Not Yet Recruiting
Not Yet RecruitingNCT07484724
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS212 | JS212 will be administered every 3 weeks |
| DRUG | JS001 | JS001 will be administered every 3 weeks |
| DRUG | 5-FU | 5-FU will be administered on d1and d8 every 3 weeks |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-06-30
- Completion
- 2028-04-01
- First posted
- 2026-03-20
- Last updated
- 2026-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07484724. Inclusion in this directory is not an endorsement.